ADVFN US – Market Content Editor

Strong quarterly results exceed Wall Street forecasts First BanCorp. (NYSE:FBP) reported better-than-expected second-quarter 2026 results on Wednesday, as higher net interest income and continued loan growth helped drive a solid increase in profitability. The bank posted adjusted earnings per share of $0.62, surpassing analysts’ consensus estimate of $0.54 by $0.08. Revenue reached $264.86 million, slightly…

Customer project delay prompts weaker forecast Adtran Holdings (NASDAQ:ADTN) shares dropped 14% on Wednesday after the networking equipment provider lowered its preliminary second-quarter 2026 revenue outlook, citing a delay to a major customer project. The company now expects second-quarter revenue to be between $280.0 million and $282.0 million, below its previous guidance of $283.0 million…

Discounted share sale weighs on stock Dyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approximately $375 million. The offering was priced at $20.50 per share, representing a discount of about 14% to Tuesday’s closing price of $23.83, contributing to the…

Revenue beats expectations as acquisition costs weigh on profit Iridium Communications Inc. (NASDAQ:IRDM) reported second-quarter 2026 results on Wednesday that topped revenue expectations but fell short on earnings, as costs related to its pending acquisition by Rocket Lab weighed on profitability. The satellite communications company posted adjusted earnings per share of $0.09, below the analyst…

Record quarterly profit tops Wall Street expectations Old National Bancorp (NASDAQ:ONB) reported stronger-than-expected second-quarter 2026 results on Wednesday, driven by higher revenue, solid loan growth and record profitability. The bank posted adjusted earnings per share of $0.65, ahead of the analyst consensus estimate of $0.63. Revenue on a fully taxable equivalent basis totaled $740.06 million,…

New lymphoma results support development programme Curis, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the biotechnology company released encouraging updated clinical data for emavusertib in patients with Primary CNS Lymphoma (PCNSL) and raised enrollment expectations for its Chronic Lymphocytic Leukemia (CLL) study. Updated findings from the TakeAim Lymphoma trial showed an overall response rate…

New survival data supports ivonescimab treatment Summit Therapeutics Inc. (NASDAQ:SMMT) shares gained 3% on Wednesday after the company released updated overall survival data from its global Phase III HARMONi trial evaluating ivonescimab in combination with chemotherapy for advanced lung cancer. The study enrolled patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer…

Late-stage studies achieve all primary and secondary goals Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares jumped 18% on Wednesday after the company announced positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials evaluating plozasiran in patients with severe hypertriglyceridemia. Both studies successfully met their primary endpoint of reducing triglyceride levels compared with placebo, while…

Strong sales growth drives earnings outperformance Oatly Group AB (NASDAQ:OTLY) reported stronger-than-expected second-quarter 2026 results on Wednesday, with robust revenue growth prompting the company to raise its full-year sales outlook. The oat-based beverage maker generated revenue of $240.1 million during the quarter, a 15% increase from a year earlier and well above analysts’ consensus estimate…

Earnings and revenue surpass Wall Street expectations Northern Trust Corporation (NASDAQ:NTRS) reported second-quarter 2026 results that comfortably exceeded analyst forecasts, supported by higher fee income and a significant gain related to its participation in Visa’s exchange offer. The company posted adjusted earnings per share of $4.23, well above the consensus estimate of $2.70. Revenue rose…